• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CU6

CLARITY PHARMACEUTICALS LTD - News & Media

3.66% ! $4.53
Market Cap $1.699B  !
Healthcare Biotechnology
Add to My Watchlist

Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical... Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. It is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. It has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.More

Articles & Videos

Clarity scribes deal on delivery of copper 64 isotopes

Clarity Pharmaceuticals Ltd has seen its share price leap after it announced a deal with Nusano to deliver Cu-64 isotopes

17 Apr 2025 14:48 (AEST)

Another win for Clarity at FDA as imaging agent fast-tracked for complex prostate cancer

For those unlucky enough to have received a testicular castration to treat prostate cancer, only for it to come back, Clarity Pharmaceuticals’ (ASX:CU6) news on Wednesday morning could offer crucial moral support.For those patients (who have also already received first-stage less ...

19 Feb 2025 12:53 (AEDT)

Clarity jumps as FDA awards fast track status for PET scan imaging agent

Clarity Pharmaceuticals (ASX:CU6) has seen the U.S. FDA fast-track its prostate cancer imaging compound for use in PET scans on patients with recurring prostate cancer. The stock jumped 4% in the first hour of trade to $4.23 in what is likely a welcome move for shareholders who have already seen ...

24 Jan 2025 11:47 (AEDT)

Clarity progresses SECuRE trial with positive safety results

Clarity Pharmaceuticals Ltd has reported strong results from Cohort 4 of the SECuRE trial examining a treatment for prostate cancer

12 Sep 2024 12:13 (AEST)

US FDA awards Clarity Pharma's novel prostate cancer PET scan imaging compound fast track status

Clarity Pharmaceuticals (ASX:CU6) has revealed it's received fast track status from the US FDA for its prostate cancer imaging compound designed for PET scans.

22 Aug 2024 11:24 (AEST)

Clarity Pharmaceuticals achieves recruitment target for phase II SAR-Bombesin prostate cancer trial

Clarity Pharmaceuticals (ASX:CU6) has imaged 50 patients with Cu-SAR-Bombesin in its United States-based diagnostic trial, SABRE.

07 Nov 2023 11:35 (AEDT)

Clarity Pharmaceuticals' (ASX:CU6) ongoing trials reach highest dose level

Clarity Pharmaceuticals (ASX:CU6) has treated the first patient at the highest dose level of 12GBq in the third cohort of its phase I/II theranostic prostate cancer trial.

25 Aug 2023 13:14 (AEST)

Clarity Pharmaceuticals' (ASX:CU6) theranostic prostate cancer trial progresses to highest dose level

Clarity Pharmaceuticals (ASX:CU6) has accelerated its theranostic prostate cancer trial, moving into its third cohort and administering the highest dose yet of Cu SAR-bisPSMA.

10 Aug 2023 12:13 (AEST)

Clarity Pharmaceuticals (ASX:CU6) gains tick of approval to begin phase three prostate cancer trial

Clarity Pharmaceuticals (ASX:CU6) has gained approval to begin a phase three trial, assessing its 64Cu SAR-bisPSMA diagnostic in prostate cancer.

04 Jul 2023 11:22 (AEST)

Clarity Pharmaceuticals (ASX:CU6) completes recruitment for phase II prostate cancer trial

Clarity Pharmaceuticals (CU6) has completed recruitment for a phase two trial of its prostate cancer treatment Cu-SAR-Bombesin.

07 Jun 2023 14:41 (AEST)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
$4.53 		Change
0.160(3.66%) 		Mkt cap ! $1.699B
Open High Low Value Volume
$4.37 $4.64 $4.36 $7.555M 1.668M

Buyers (Bids)

No. Vol. Price($)
3 7817 $4.52
 

Sellers (Offers)

Price($) Vol. No.
$4.53 213 3
View Market Depth
Last trade - 11.17am 01/08/2025 (20 minute delay) ?
Last
$4.57 		  Change
0.160 ( 4.31 %)
Open High Low Volume
$4.42 $4.64 $4.36 237035
Last updated 11.36am 01/08/2025 ?
CU6 (ASX) Chart

Top Stories

Market shrugs off Bellevue's 'conservative' FY26 guidance

Bellevue Gold (ASX:BGL) has inked its FY26 guidance for the year ahead, and the company’s seen a muted share price reaction, dipping down -0.3% on Friday as the market assesses whether or not it likes what it’s seeing. Listen to the HotCopper podcast for in-depth d...
Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign Infini Resources’ newly appointed CEO, Rohan Bone joins The Market Online to discuss strategy moving forward. Join the discussion. See what HotCopper users are saying about Infini Resources and be part of the conversations that move the markets.The material provided in this articl...
Prospect Resources: Replicating the success of Arcadia with ~1b tonne copper ore target Executive Director, Ian Goldberg joined The Market Online to discuss their Mumbezhi Project, what could be one of the ASX’s largest copper stories.Join the discussion. See what HotCopper users are saying about Prospect Resources and be part of the conversations that move the marke...
Redcastle's 'breakout year' continues with optimistic Queen Alexandra scoping study A study run at Queen Alexandra has left Redcastle Resources (ASX:RC1) bullish on its Golden Circle-based project, with the report suggesting the WA explorer has a @high return project” on its hands @ should gold prices hold steady.Listen to the HotCopper podcast for in-depth...
ASX Market Open: Trump tariff deadline looms again – and sets up red Friday | Aug 1 Australian shares will end Week 31 on a dour note, down 70 points in futures, with Trump’s long-heralded tariffs unpause date @ which has been pushed back at the eleventh hour before @ inked in for Friday, Aug. 1 in the U.S.Listen to the HotCopper podcast for in-depth discussions ...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.